Innovative Oligonucleotide Strategies for Targeted RNA Expression Modulation

Daiichi Sankyo, a global pharmaceutical company, is seeking novel oligonucleotide-based approaches to efficiently and specifically increase or decrease target RNAs both in vitro and in vivo for developing new treatments. Additionally, cutting-edge RNA editing techniques are also of interest.

Approaches of Interest:

• Novel oligonucleotide-based technology that can control RNA expression levels or change RNA sequences e.g., dual-targeting antisense oligonucleotides (ASOs) and advanced RNA editing technologies
• Novel technologies for efficient transport from extracellular space into cytosol, nucleus or mitochondria e.g., chemically modified oligonucleotides to enhance transport from the cytosol into the nucleus
• Novel target-identification methods for oligonucleotide-based approaches such as ASO and RNA editing
• Research findings on novel biological regulatory pathways or molecules that control RNA transcription, splicing, translation, or transport, with potential for future development as described in the previous three bullet points
  • Opportunities should demonstrate how the newly identified RNA targets could contribute to treating specific diseases

Out of Scope:

• Packaging technologies/delivery systems (e.g. viral vectors, nanoparticles)
• For submissions relating to ASOs, RNA editing techniques, and conventional technologies that modulate RNA by endogenous Ago2, RNase H or ADAR are out of scope
• Submissions based on hypothetical ideas or lacking sufficient proof-of-concept

Developmental Stages of Interest:

• Submissions must include, at minimum, in vitro data; in vivo data is preferred 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Our client is also open to novel research proposals which can be outlined using this submission form. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.